A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas

Inclusion Criteria:

   - Pathologically documented relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
   or follicular lymphoma (FL)

   - Measurable disease sites on CT scan (>1.5 cm in longest dimension)

   - Adequate hematologic function:

      1. Absolute Neutrophil Count >1500 cells/mm3

      2. Platelets >50000 cells/mm3

      3. Hemoglobin >8.0 g/dL

   - Adequate hepatic and renal function:

      1. AST or ALT ≤2.5 x ULN

      2. Bilirubin ≤1.5 x ULN

      3. Estimated creatinine clearance (Cockcroft-Gault) >40 mL/min

   - ECOG 0 or 1

Exclusion Criteria:

   - Received prior therapies: ibrutinib, or other BTK inhibitor and/or anti-PD1,
   anti-PD-L1, anti-PD-L2, anti-CD137, or CTLA-4 antibody

   - Requires treatment or prophylaxis with a strong cytochrome P450 (CYP) 3A inhibitor

   - Primary CNS lymphoma or evidence of CNS involvement by lymphoma